| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 Million |
| 09 Nov 2026 |
8-K: Regulation FD Disclosure
CULVER CITY, Calif., November 9, 2026—ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced positive results from the final analysis of the primary endpoint in Cohort A of QUILT-2.005, a randomized, ... |
| 14 Oct 2026 |
8-K: Regulation FD Disclosure
FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle- Invasive Bladder Cancer to Cover Both Papillary and CIS Disease |
| 04 Aug 2026 |
8-K: Results of Operations and Financial Condition
CULVER CITY, Calif. August 4, 2026 — ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage biotechnology company, today announced financial and operational results for the second quarter ended June 30, 2026. Net product revenue reached $5... |
| 30 Jul 2026 |
8-K: Regulation FD Disclosure
CULVER CITY, Calif., July 29, 2026 — ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated commercial-stage biotechnology company, today announced that the Emirates Drug Establishment (EDE) of the United Arab Emirates (UAE) has grant... |
| 10 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 9, 2026, ImmunityBio, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Of the 1,047,345,861 shares of our common stock, par value $0.0001 per share (“Common Stock”) outstanding as of April... |
| 18 May 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
CULVER CITY, Calif. May 7, 2026 — ImmunityBio, Inc. (NASDAQ: IBRX), a biotechnology company, announced financial and operational highlights for the fiscal quarter ended March 31, 2026. The Company reported net product revenue of approxim... |
| 09 Apr 2026 |
8-K: Results of Operations and Financial Condition
CULVER CITY, Calif., Apr. 9, 2026 — ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage biotechnology company, announced today preliminary select operational results for the fiscal quarter ending March 31, 2026. ImmunityBio reported pre... |
| 06 Apr 2026 |
8-K: Regulation FD Disclosure
Company initiated a comprehensive review of promotional materials and is implementing enhanced advertising compliance measures, including expanded promotional review protocols, executive training, and external regulatory oversight |
| 31 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more
This SECOND AMENDMENT TO REVENUE INTEREST PURCHASE AGREEMENT (this “Amendment”), dated as of the date first set forth above, is entered into by and among (i) ImmunityBio, Inc., a Delaware corporation (the “Company”), (ii) solely with res... |
| 23 Feb 2026 |
8-K: Results of Operations and Financial Condition
CULVER CITY, Calif. February 23, 2026:ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced full-year 2025 financial and operational highlights, including approximately $113 million in net product re... |
| 18 Feb 2026 |
8-K: Other Events
CULVER CITY, Calif., February 18, 2026 — ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the European Commission has granted conditional marketing authorization for ANKTIVA® (nogapendekin alfa i... |
| 26 Jan 2026 |
8-K: Entry into a Material Definitive Agreement
Reference is made to that certain Second Amended and Restated Promissory Note issued by ImmunityBio, Inc., a Delaware corporation (the “Company”) to Nant Capital, LLC, a Delaware limited liability company (the “Holder”), dated December 1... |
| 15 Jan 2026 |
8-K: Results of Operations and Financial Condition
CULVER CITY, Calif., Jan. 15, 2026 — ImmunityBio, Inc. (NASDAQ: IBRX), a vertically-integrated commercial stage biotechnology company, announced today preliminary select operational results for the fiscal quarter and full year ending Dec... |
| 14 Jan 2026 |
8-K: Other Events
CULVER CITY, Calif., January 14, 2026 – ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug Authority (SFDA) has granted approval of ANKTIVA® (nogapendekin alfa inbakic... |
| 29 Dec 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
This Amendment No. 1 to Open Market Sale AgreementSM (this “Amendment”) is entered into as of the date first written above by ImmunityBio, Inc., a Delaware corporation (the “Company”), and Jefferies LLC, as sales agent and/or principal (... |
| 15 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On December 10, 2025, the board of directors (the “Board”) of ImmunityBio, Inc. (the “Company”) appointed Bruce Wendel to the Board, effective as of December 12, 2025 (the “Effective Date”), with a term expiring at the Company’s 2026 ann... |
| 12 Dec 2025 |
8-K: Other Events
CULVER CITY, Calif., December 12, 2025 – ImmunityBio (NASDAQ: IBRX), a leading immunotherapy company, announced today that the European Medicines Agency has recommended granting a conditional marketing authorization in the EU for ANKTIVA... |
| 05 Nov 2025 |
8-K: Results of Operations and Financial Condition
CULVER CITY, Calif. — November 4, 2025 — ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced its financial results for the fiscal quarter and nine months ended September 30, 2025. |
Loading...